-+ 0.00%
-+ 0.00%
-+ 0.00%

Chosa Oncology Q3 pretax loss narrows 38% to SEK 1.57 million

PUBT·11/19/2026 07:32:14
Listen to the news
Chosa Oncology Q3 pretax loss narrows 38% to SEK 1.57 million
  • Chosa Oncology’s third-quarter 2026 loss after financial items narrowed 38% year over year to SEK 1.57 million.
  • A global, non-exclusive licensing agreement with AIDA Oncology granted reciprocal rights to Platin-DRP for breast cancer and TaxaTect for lung cancer.
  • A November agreement secured a CLIA-certified laboratory partner for US Platin-DRP commercialization, with first revenue expected in summer 2027.
  • The board authorized a rights issue of units worth approximately SEK 2.5 million, fully secured through subscription commitments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 202611190230BITN____UKPR__SV_20261118-BIT-1137-0) on November 19, 2026, and is solely responsible for the information contained therein.